ASTMH 2014 - #IamTropMed

Stephan Chalon, Medical Director, MMV

"#IamTropMed because I want to develop new antimalarials for pregnant women"

1. Why did you decide to go into your area of work?

A raft of unmet medical needs exist in the area of malaria treatment for children and pregnant women, people suffering from severe malaria, relapsing malaria, and artemisinin-resistant malaria. I want to use my skills and expertise to develop new, effective antimalarials, ideally single-dose cures for these unmet needs.

2. What do you enjoy most about working in your area of research?

The most rewarding part of my work is seeing promising, next-generation compounds progress through into first-in-human clinical trials and to evaluate their safety and efficacy before they are tested in patients.

3. What developments over the past year have been most exciting to you?

In 2014 we started a first-in-human study with MMV390048, a new antimalarial, in South-Africa. This is exciting because MMV390048 is the first antimalarial compound discovered and researched on African soil and is the product of an international collaboration. We are keenly monitoring its progress through human volunteers.